Patents by Inventor Darren H. Wakefield

Darren H. Wakefield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120172412
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Application
    Filed: December 23, 2011
    Publication date: July 5, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Patent number: 8211468
    Abstract: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: July 3, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom, Kirk Ekena
  • Publication number: 20120165393
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Application
    Filed: December 15, 2011
    Publication date: June 28, 2012
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffman, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Publication number: 20120157509
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Application
    Filed: December 15, 2011
    Publication date: June 21, 2012
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B. Rozema, David L. Lewis, Darren H. Wakefield
  • Patent number: 8138383
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Patent number: 8137695
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, James E. Hagstrom, Jason Klein, David L. Lewis, Sean D. Monahan, Darren H. Wakefield, Jon A. Wolff, So Wong
  • Patent number: 8017109
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 13, 2011
    Assignee: Roche Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 8008355
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20110207799
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: ROCHE MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 7985406
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: July 26, 2011
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7501394
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: March 10, 2009
    Assignee: Roche Madison Inc.
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren H. Wakefield, Magdolna G. SebestyƩn
  • Publication number: 20090048410
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: February 19, 2009
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20090023890
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: January 22, 2009
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7470539
    Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: December 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, Vladimir Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jason Klein, So Wong
  • Publication number: 20080287630
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080287628
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080281044
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 13, 2008
    Inventors: Sean D. Monahan, Lori Higgs, Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080281041
    Abstract: The present invention is directed to reversibly inactivation of membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 13, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080269450
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: October 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Andrei Blokhin, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080152661
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 26, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jason Klein, So Wong, Jon A. Wolff, David L. Lewis, James E. Hagstrom, Andrei Blokhin, Vladimir Trubetskoy, Hans Herweijer